4//SEC Filing
Salkind Gene 4
Accession 0001683168-24-000161
CIK 0001759186other
Filed
Jan 8, 7:00 PM ET
Accepted
Jan 9, 5:31 PM ET
Size
7.2 KB
Accession
0001683168-24-000161
Insider Transaction Report
Form 4
Salkind Gene
Director
Transactions
- Purchase
Common Stock
2024-01-05$0.69/sh+11,600$8,004→ 284,056 total
Holdings
- 28,638(indirect: By Trust)
Common Stock
- 4,046(indirect: By Trust)
Common Stock
Footnotes (4)
- [F1]Includes (i) 95,817 shares of common stock that are held as JTWROS with Catherine Salkind, (ii) 57,268 shares of common stock issuable upon exercise of currently exercisable warrants held as JTWROS with Catherine Salkind, (iii) 101,061 shares of common stock that are issuable upon currently exercisable warrants and (iv) 30,000 shares of common stock that are issuable upon exercise of options that are or will become exercisable in the next 60 days.
- [F2]These shares were not subject to a particular transaction during the dates covered by this Form 4 and are listed here to disclose the Reporting Person's holdings as required by Securities and Exchange Commission rules.
- [F3]The Marital Trust GST Subject U/W/O Leopold Salkind, for which the Reporting Person is the Trustee.
- [F4]Julian R Salkind Trust DTD 10/11/94, for which the Reporting Person is the Trustee.
Documents
Issuer
Coeptis Therapeutics Holdings, Inc.
CIK 0001759186
Entity typeother
Related Parties
1- filerCIK 0001592481
Filing Metadata
- Form type
- 4
- Filed
- Jan 8, 7:00 PM ET
- Accepted
- Jan 9, 5:31 PM ET
- Size
- 7.2 KB